Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | ITK | Q08881 | 1/20 | 0.31 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4694751 | 0.93 | GRM1 (0.42) | GRM1OPRM1OPRK1PDE1BITK | |
| SCHEMBL4689711 | 0.83 | GRM1 (0.38) | GRM1ITK | |
| Hydrochloric Acid SCHEMBL4692161 | 0.83 | CNR2 (0.39) | GRM1ITKMETTL3MCHR1 | |
| Hydrochloric Acid SCHEMBL5546328 | 0.82 | GRM1 (0.37) | GRM1ITK | |
| SCHEMBL4688067 | 0.82 | GRM1 (0.38) | GRM1ITKMETTL3 | |
| SCHEMBL7241308 | 0.81 | GRM1 (0.44) | GRM1ITKMETTL3 | |
| Hydrochloric Acid SCHEMBL7241481 | 0.80 | GRM1 (0.43) | GRM1ITKMETTL3 | |
| Hydrochloric Acid SCHEMBL4692131 | 0.80 | GRM1 (0.40) | GRM1ITKMETTL3 | |
| SCHEMBL4693948 | 0.80 | GRM1 (0.40) | GRM1ITK | |
| SCHEMBL7233838 | 0.80 | GRM1 (0.43) | GRM1ITKMETTL3MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1486501-B1 | AMINOMETHYL-SUBSTITUTED THIAZOLOBENZIMIDAZOLE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-7250429-B2 | Aminomethyl-substituted thiazolobenzimidazole compounds | ASTELLAS PHARMA INC. (JP) | 2007-07-31 | — | — | US | disclosed |
| US-20050148642-A1 | Aminomethyl-substituted thiazolobenzimidazole derivative | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1486501-A1 | AMINOMETHYL-SUBSTITUTED THIAZOLOBENZIMIDAZOLE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148642-A1 | Aminomethyl-substituted thiazolobenzimidazole derivative | GRM1, GRIN1, GRM3 | GRM1 1/4885OPRM1 51/4885OPRK1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.